Мальта - англійська - Medicines Authority

octapharma (ip) limited - human coagulation factor ix - powder and solvent for solution for injection - human coagulation factor ix 1000 iu - antihemorrhagics

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - nonacog alfa, quantity: 3000 iu - injection, powder for - excipient ingredients: polysorbate 80; sucrose; histidine; glycine - benefix is indicated for the control and prevention of haemorrhagic episodes in patients with haemophilia b (congenital factor ix deficiency or christmas disease), including control and prevention of bleeding in surgical settings. benefix is not indicated for the treatment of other factor deficiencies (e.g. factors ii, vii and x), nor for the treatment of haemophilia a patients with inhibitors to factor viii, nor for the reversal of coumarin induced anti-coagulation, nor for the treatment of bleeding due to low levels of liver-dependent coagulation factors.

США - англійська - NLM (National Library of Medicine)

cangene biopharma - coagulation factor ix recombinant human (unii: 382l14738l) (coagulation factor ix recombinant human - unii:382l14738l) - coagulation factor ix recombinant human 500 [iu] in 5 ml

Мальта - англійська - Medicines Authority

csl behring gmbh emil-von-behring-strasse 76, 35041 marburg, germany - factor ii, prothrombin, factor vii, human, factor x, factor ix, protein c - powder and solvent for solution for injection - factor ii (prothrombin) 20-48 iu factor vii, human 10-25 iu factor x, human 22-60 iu factor ix, human 20-31 iu protein c 15-45 iu - antihemorrhagics

Мальта - англійська - Medicines Authority

csl behring gmbh emil-von-behring-strasse 76, 35041 marburg, germany - factor ii, prothrombin, factor vii, human, factor ix, factor x, protein c - powder and solvent for solution for injection - factor ii (prothrombin) 20-48 iu factor vii, human 10-25 iu factor ix, human 20-31 iu factor x, human 22-60 iu protein c 15-45 iu - antihemorrhagics

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - factor viii, quantity: 500 iu; von willebrand factor, quantity: 1200 iu - injection, diluent for - excipient ingredients: - the prophylaxis and treatment of non-surgical and surgical bleeding in patients with von willebrand disease when desmopressin (ddavp) treatment is ineffective or contraindicated. the prophylaxis and treatment of non-surgical and surgical bleeding associated with factor viii deficiency due to haemophilia a.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - factor viii, quantity: 250 iu; von willebrand factor, quantity: 600 iu - injection, diluent for - excipient ingredients: - the prophylaxis and treatment of non-surgical and surgical bleeding in patients with von willebrand disease when desmopressin (ddavp) treatment is ineffective or contraindicated. the prophylaxis and treatment of non-surgical and surgical bleeding associated with factor viii deficiency due to haemophilia a.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - factor ix, quantity: 500 iu - injection, diluent for - excipient ingredients: water for injections - monofix-vf is indicated for the treatment of haemorrhages, for use in surgery, and as prophylaxis in patients with haemophilia b. monofix-vf is not indicated for the treatment of factor ii, vii or x deficiencies because it does not contain therapeutic levels of these coagulation factors. monofix-vf is not indicated for the treatment of haemophilia a patients with factor viii inhibitors.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - factor ix, quantity: 500 iu - injection, diluent for - excipient ingredients: water for injections - monofix-vf is indicated for the treatment of haemorrhages, for use in surgery, and as prophylaxis in patients with haemophilia b. monofix-vf is not indicated for the treatment of factor ii, vii or x deficiencies because it does not contain therapeutic levels of these coagulation factors. monofix-vf is not indicated for the treatment of haemophilia a patients with factor viii inhibitors.

Мальта - англійська - Medicines Authority

octapharma (ip) sprl alle de la recherche 65, 1070 (anderlecht), belgium - human coagulation, factor ix - powder and solvent for solution for injection - human coagulation factor ix 500 iu - antihemorrhagics